| NCT ID | NCT04495790 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Advanced Integrative Medical Science Institute |
| Condition | Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-05-18 |
| Primary Completion | 2025-05-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2020-05-18 with a primary completion date of 2025-05-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Eligibility Criteria
Inclusion Criteria: 1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or 2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute; 3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment; 4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient; 5. A confirmed diagnosis of cancer based on medical oncology medical records. Exclusion Criteria: 1. Patients not diagnosed with cancer; 2. Telehealth patients; 3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires; 4. Unwilling to participate in the AIMS Institute observational study.
Frequently Asked Questions
Who can join the NCT04495790 clinical trial?
This trial is open to participants of all sexes, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04495790 currently recruiting?
Yes, NCT04495790 is actively recruiting participants. Visit ClinicalTrials.gov or contact Advanced Integrative Medical Science Institute to inquire about joining.
Where is the NCT04495790 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT04495790 clinical trial?
NCT04495790 is sponsored by Advanced Integrative Medical Science Institute. The trial plans to enroll 500 participants.